3 Large Cap Stocks To Buy Before Year End

If you’ve been keeping up with the news, you might have seen that in Q2 2025, the U.S. economy grew by 4.3%. This far outpaced expectations of 3.2%. In tandem, expectations of short-term volatility reached a yearly low, with the VIX closing at 13.6.

So, how did the markets react? Positively, but not overwhelmingly so. Last week, the S&P 500 rose by 0.75% — and as is often the case, the gains were relatively concentrated. Whereas small-caps and mid-caps saw declines or negligible gains, large-cap stocks saw an appreciable rise.

Caution is always warranted, since we’re not out of the woods yet. But at present, analysts are expecting earnings to grow by an average of 15% in 2026. In addition, growth is expected in all 11 sectors, with information technology leading the charge

It’s little surprise that large-caps absorbed the brunt of the gains, and it seems like that will continue to be the case in the weeks to come. A rotation seems to already be underway.

However, it’s clear that the easy gains have already been made — to succeed in 2026, you’re going to have to do a bit of stock picking. Thankfully, that doesn’t have to be difficult or time consuming — provided you turn to our…

Large Cap Stock Strategy

Thanks to our proprietary quant model, we can evaluate roughly 4,600 stocks on a daily basis. By using 115 unique factors, we can get a holistic overview of a stock — and we distill down into a single metric, our Zen Rating.

To qualify for a Zen Rating of A, equivalent to a Strong Buy rating, a stock has to rank in the top 5% of the equities that we track. With that being said, that’s still roughly 230 stocks for you to look at.

However, you don’t have to — you can make the whole process even more efficient by taking a look at one of our exclusive Zen Strategies.

There are 11 Zen Strategy portfolios in total, and each consists of just 7 carefully selected stocks. As you might expect, we’ll be taking a look at our Large Caps Stock Strategy today.

Over the course of this year, the portfolio has provided a 37.26% return, far outpacing the S&P 500’s 17.57% gain in the same timeframe. There’s quite a bit of momentum here as well — as the strategy has provided a 5.43% gain since the start of December.

Now, let’s take a look at 3 promising, fairly-valued stocks from the portfolio…

Textron (TXT)

This diversified industrial aerospace manufacturer is best known as the owner of the Cessna brand of aircraft. TXT currently ranks in the top 2% of the 4600+ stocks that we track, giving it a Zen Rating of A, and it also ranks 86th overall on our list.

Textron had a good year in 2025 — the stock rallied by 17.09%, although that isn’t surprising, seeing as how the business has beaten earnings estimates for 4 quarters in a row. What is surprising, however, is how great TXT’s valuation is relative to its growth prospects. In terms of Value, Textron shares rank in the top 3% on the Zen Ratings — in terms of Growth, they rank in the top 8%.

That isn’t everything, however. This is a stable, mature business — and when it comes to the Safety Component Grade rating, it’s in the 95th percentile — equivalent to or better than 95% of stocks, or, in other words, in the top 5%. To cap everything off, we have a solid balance sheet, which gives TXT a place in the top 22% of equities in terms of Financials.

At a P/E of  just 19.61x and a PEG ratio of 1.05x, TXT is currently a steal — and seeing as how the company’s next earnings call, due January 28, isn’t all that far away, locking in the discount on offer might be the wisest course of action.

Bristol Myers Squibb (BMY)

A 111$ billion market cap titan, Bristol Myers Squibb is one of the world’s largest pharma companies. Currently, BMY is the 25th highest-rated stock on our list — it ranks in the top 1% of stocks on the whole, and it’s the 2nd highest-rated stock in its industry. (Check out another top-rated pharma stock for 2026 here.)

Like with our previous entry, we have a proven track record of outperformance, an appealing valuation, and great growth prospects. BMY has notched 9 earnings beats in a row — however, it still ranks in the top 3% for Value as well as the top 12% for Growth. To put that in perspective, Bristol Myers Squibb shares are trading at a P/E of just 18.4x and a PEG of 0.72x — while earnings are forecast to grow at 25.4% per year.

We also have a pretty strong balance sheet here, as well as Wall Street’s seal of approval — BMY is in the top 10% for Financials and the 91st percentile for Sentiment.

However, what really stands out here is Safety — as a well-established, mature business, BMY ranks in the top 6% in this category. The stock’s beta stands at a very low 0.3 — making it a real no-brainer if you’re looking for a long-term, buy-and-hold pick.

Micron (MU)

Last, but certainly not least, is Micron — which ranks in the top 1% of the stocks that we track, and is currently rated 24th overall out of roughly 4,600. Currently the top-rated stock in the Semiconductor industry, MU ranks in the top 5% of stocks for Momentum, owing to a staggering 237.08% YTD rally.

Normally, surges like those make a stock overvalued — but that isn’t the case here. MU’s P/E ratio sits at just 26.79x — and its PEG ratio is at just 0.66x. On the whole, this puts it in the top 5% of stocks in terms of Value. However, Micron’s growth prospects are equally as impressive — with earnings forecast to grow at a rate of 40.31% per year, the stock is also in the 92nd percentile for Growth.

Just like with our previous picks, we have a strong balance sheet — MU is in the top 4% of stocks in terms of Financials. To boot, Wall Street is pretty optimistic — Micron falls in the top 11% of equities in terms of Sentiment, owing to an 11-quarter earnings beat streak.

Right now, this is the best play in semiconductors by a long shot — and since it’s trading close to its 52-week high, we could soon see MU reaching new ATH levels.

Interested In More Great Stock Picks?

The 3 stocks highlighted above are just a fraction of what you get from our proven Large Caps Stock strategy. 

That’s because each day our system recalibrates — and Zen Strategies members get access to the 7 top Buy the Dip stocks based on 115 different parameters that point to outperformance. 

See all Top 7 Large Cap Stocks here > 

However, maybe large cap stocks aren’t what you’re interested in right now. Perhaps you would like to see all 11 of our market beating strategies including Growth, Momentum, Technology, and our coveted AI Factor model. 

Each featuring the top 7 stocks.

Each featuring tremendous performance

We spell it all out in this timely presentation below that lives up to its name:

10 Minutes a Month to Beat the Market > 

What to Do Next?

• 77 Best Stocks NOW! >
• See All “A” Rated Stocks with +32.52% Average Annual Return >
• 2 New Stocks to Buy from Steve Reitmeister >

Want to get in touch? Email us at news@wallstreetzen.com.